BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate

Reuters03-21

BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate

** Immunovant IMVT.O said on Wednesday its experimental treatment, batoclimab, for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer drug

** Analysts are looking into the development of IMVT-1402, the company's lead therapy candidate and its additional indications for autoimmune disorders

BEST-IN-CLASS AUTOIMMUNE THERAPY EMERGING

** Leerink Partners ("outperform", PT: $52) says the next-gen IMVT-1402 has a competitive advantage due to its convenient, low-volume dosage and is optimistic about the additional data due in 2026

** J.P.Morgan says IMVT-1402 will "outshine others" in indications such as Graves' disease and rheumatoid arthritis

** Oppenheimer Securities ("outperform", PT: $54) believes company's drug, IMVT-1402, has the potential to become the "preferred therapy for several autoimmune disorders"

** Truist Securities views Argenx's ARGX.BR Vyvgart's "first mover advantage coupled with physician comfort" will continue to make it the preferred agent ahead of IMVT-1402 and other competitors

(Reporting by Padmanabhan Ananthan)

((padmanabhan.ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521946101?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-21 00:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521946101","market":"nz","top_or_hot":-1,"title":"BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate</title></head><body><p>** Immunovant <span>IMVT.O</span> said <span>on Wednesday</span> its experimental treatment, batoclimab, for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer drug</p><p>** Analysts are looking into the development of IMVT-1402, the company's lead therapy candidate and its additional indications for autoimmune disorders</p><p>BEST-IN-CLASS AUTOIMMUNE THERAPY EMERGING</p><p>** Leerink Partners (\"outperform\", PT: $52) says the next-gen IMVT-1402 has a competitive advantage due to its convenient, low-volume dosage and is optimistic about the additional data due in 2026 </p><p>** J.P.Morgan says IMVT-1402 will \"outshine others\" in indications such as Graves' disease and rheumatoid arthritis </p><p>** Oppenheimer Securities (\"outperform\", PT: $54) believes company's drug, IMVT-1402, has the potential to become the \"preferred therapy for several autoimmune disorders\"</p><p>** Truist Securities views Argenx's <span>ARGX.BR</span> Vyvgart's \"first mover advantage coupled with physician comfort\" will continue to make it the preferred agent ahead of IMVT-1402 and other competitors</p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((padmanabhan.ananthan@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-21 00:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate</title></head><body><p>** Immunovant <span>IMVT.O</span> said <span>on Wednesday</span> its experimental treatment, batoclimab, for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer drug</p><p>** Analysts are looking into the development of IMVT-1402, the company's lead therapy candidate and its additional indications for autoimmune disorders</p><p>BEST-IN-CLASS AUTOIMMUNE THERAPY EMERGING</p><p>** Leerink Partners (\"outperform\", PT: $52) says the next-gen IMVT-1402 has a competitive advantage due to its convenient, low-volume dosage and is optimistic about the additional data due in 2026 </p><p>** J.P.Morgan says IMVT-1402 will \"outshine others\" in indications such as Graves' disease and rheumatoid arthritis </p><p>** Oppenheimer Securities (\"outperform\", PT: $54) believes company's drug, IMVT-1402, has the potential to become the \"preferred therapy for several autoimmune disorders\"</p><p>** Truist Securities views Argenx's <span>ARGX.BR</span> Vyvgart's \"first mover advantage coupled with physician comfort\" will continue to make it the preferred agent ahead of IMVT-1402 and other competitors</p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((padmanabhan.ananthan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q318R:1","article_id":"2521946101","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521946101","pubTimestamp":1742489055,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate** Immunovant IMVT.O said on Wednesday its experimental treatment, batoclimab, for a type of chronic ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","IMVT":"Immunovant, Inc.","BK4588":"碎股"},"translate_title":"BUZZ–街景：分析师等待主要候选药物的数据，Immunovant的肌肉药物显示出潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":0.9},"content_text":"BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate** Immunovant IMVT.O said on Wednesday its experimental treatment, batoclimab, for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer drug** Analysts are looking into the development of IMVT-1402, the company's lead therapy candidate and its additional indications for autoimmune disordersBEST-IN-CLASS AUTOIMMUNE THERAPY EMERGING** Leerink Partners (\"outperform\", PT: $52) says the next-gen IMVT-1402 has a competitive advantage due to its convenient, low-volume dosage and is optimistic about the additional data due in 2026 ** J.P.Morgan says IMVT-1402 will \"outshine others\" in indications such as Graves' disease and rheumatoid arthritis ** Oppenheimer Securities (\"outperform\", PT: $54) believes company's drug, IMVT-1402, has the potential to become the \"preferred therapy for several autoimmune disorders\"** Truist Securities views Argenx's ARGX.BR Vyvgart's \"first mover advantage coupled with physician comfort\" will continue to make it the preferred agent ahead of IMVT-1402 and other competitors (Reporting by Padmanabhan Ananthan) ((padmanabhan.ananthan@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521946101","isCrawlerRequest":true}